Depressive Disorder News and Research

RSS

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012

Cognitive behavioral therapy for anxiety-related dizziness

Patients with chronic subjective dizziness that is related to anxiety may substantially benefit from a short course of cognitive behavioral therapy, report researchers.

4 Dec 2012

Subthreshold bipolarity common in major depressive disorder

Results from a Polish study show that a substantial proportion of patients with major depressive disorder meet criteria for subthreshold bipolarity.

27 Nov 2012

Speed of depression onset increased in bipolar patients

Depressive episodes take significantly less time to develop in patients with bipolar disorder than in those with unipolar depression, German study findings confirm.

13 Nov 2012

Family history of schizophrenia ups risk for nonpsychotic disorders

Individuals with a family history of schizophrenia are at a significantly increased risk for a wide range of nonpsychotic DSM-IV axis I psychiatric disorders, US research shows.

8 Nov 2012

Reduced hedonic capacity in euthymic bipolar patients

Euthymic patients with bipolar disorder and remitted patients with major depressive disorder show reduced hedonic capacity compared with mentally healthy individuals, Italian researchers report.

8 Nov 2012

Family history of schizophrenia ups risk for nonpsychotic disorders

Individuals with a family history of schizophrenia are at a significantly increased risk for a wide range of nonpsychotic DSM-IV axis I psychiatric disorders, US research shows.

8 Nov 2012

Controlling depression can improve health status and social functioning in patients with heart failure

Controlling depression in patients with heart failure can improve health status, social functioning and quality of life, according to a new study by psychiatrists and cardiologists at the UC Davis and Duke University schools of medicine.

1 Nov 2012

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates, and other characteristics compared with those with major depression alone, research shows.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

MDD with subthreshold hypomania ‘should be merged with bipolar II’

Patients with major depressive disorder plus subthreshold hypomania exhibit significant differences in disease course, symptoms, treatment-seeking rates and other characteristics compared with those with major depression alone, research shows.

10 Oct 2012

Major depression goes unnoticed in pregnant women

Healthcare professionals looking after pregnant women should maintain a high level of awareness for the possibility of major depressive disorder, say US researchers who found the condition frequently goes undetected.

5 Oct 2012

Fluoxetine increases offensive aggression and alters brain development in adolescent hamsters

Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.

3 Oct 2012

BD family history risk factor for recurrent episodes in MDD

A family history of bipolar disorder increases the likelihood of recurrent episodes of hypomania or mania in individuals with prior major depressive disorder, suggest findings published in Bipolar Disorders.

1 Oct 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Executive attention deficits in youth at risk for mood disorders

Young people with a parental history of bipolar disorder or major depressive disorder have slower reaction times on tests of executive attention than those with mentally healthy parents, US researchers report.

20 Sep 2012

Mood disorder, anxiety risk elevated in children with mood disordered parents

Children with a parental history of bipolar disorder or major depressive disorder are at increased risk for any mood or anxiety disorder, research shows.

19 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012